Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 94

1.

Infections: a double-edge sword in autoimmunity.

Shamriz O, Shoenfeld Y.

Curr Opin Rheumatol. 2018 Jul;30(4):365-372. doi: 10.1097/BOR.0000000000000490.

PMID:
29847440
2.

Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity.

Harley JB, Chen X, Pujato M, Miller D, Maddox A, Forney C, Magnusen AF, Lynch A, Chetal K, Yukawa M, Barski A, Salomonis N, Kaufman KM, Kottyan LC, Weirauch MT.

Nat Genet. 2018 May;50(5):699-707. doi: 10.1038/s41588-018-0102-3. Epub 2018 Apr 16.

PMID:
29662164
3.

Effects of Type 1 Diabetes Risk Alleles on Immune Cell Gene Expression.

Ram R, Morahan G.

Genes (Basel). 2017 Jun 21;8(6). pii: E167. doi: 10.3390/genes8060167. Review.

4.

Seasonality and autoimmune diseases: The contribution of the four seasons to the mosaic of autoimmunity.

Watad A, Azrielant S, Bragazzi NL, Sharif K, David P, Katz I, Aljadeff G, Quaresma M, Tanay G, Adawi M, Amital H, Shoenfeld Y.

J Autoimmun. 2017 Aug;82:13-30. doi: 10.1016/j.jaut.2017.06.001. Epub 2017 Jun 16. Review.

PMID:
28624334
5.

A Histological Study of Fulminant Type 1 Diabetes Mellitus Related to Human Cytomegalovirus Reactivation.

Yoneda S, Imagawa A, Fukui K, Uno S, Kozawa J, Sakai M, Yumioka T, Iwahashi H, Shimomura I.

J Clin Endocrinol Metab. 2017 Jul 1;102(7):2394-2400. doi: 10.1210/jc.2016-4029.

PMID:
28398495
6.

Posttransplant Lymphoproliferative Disorder After Clinical Islet Transplantation: Report of the First Two Cases.

Peters A, Olateju T, Deschenes J, Shankarnarayan SH, Chua N, Shapiro AMJ, Senior P.

Am J Transplant. 2017 Sep;17(9):2474-2480. doi: 10.1111/ajt.14303. Epub 2017 May 18.

PMID:
28390107
7.

Comorbidities treated in primary care in children with chronic fatigue syndrome / myalgic encephalomyelitis: A nationwide registry linkage study from Norway.

Bakken IJ, Tveito K, Aaberg KM, Ghaderi S, Gunnes N, Trogstad L, Magnus P, Stoltenberg C, Håberg SE.

BMC Fam Pract. 2016 Sep 2;17(1):128. doi: 10.1186/s12875-016-0527-7.

8.

Primary central nervous system posttransplant lymphoproliferative disease: An uncommon diagnostic dilemma.

Degen D, Kanellis J, Hughes P, Barit D, Ierino F.

Nephrology (Carlton). 2016 Jun;21(6):528. doi: 10.1111/nep.12626. No abstract available.

PMID:
27188412
9.

Multivariate eQTL mapping uncovers functional variation on the X-chromosome associated with complex disease traits.

Brumpton BM, Ferreira MA.

Hum Genet. 2016 Jul;135(7):827-39. doi: 10.1007/s00439-016-1674-6. Epub 2016 May 7.

PMID:
27155841
10.

T-cell libraries allow simple parallel generation of multiple peptide-specific human T-cell clones.

Theaker SM, Rius C, Greenshields-Watson A, Lloyd A, Trimby A, Fuller A, Miles JJ, Cole DK, Peakman M, Sewell AK, Dolton G.

J Immunol Methods. 2016 Mar;430:43-50. doi: 10.1016/j.jim.2016.01.014. Epub 2016 Jan 28.

11.

Immunoproteomic Profiling of Antiviral Antibodies in New-Onset Type 1 Diabetes Using Protein Arrays.

Bian X, Wallstrom G, Davis A, Wang J, Park J, Throop A, Steel J, Yu X, Wasserfall C, Schatz D, Atkinson M, Qiu J, LaBaer J.

Diabetes. 2016 Jan;65(1):285-96. doi: 10.2337/db15-0179. Epub 2015 Oct 8.

12.

Post-transplant lymphoproliferative disorder after kidney transplantation: time to adopt monitoring of Epstein-Barr virus?

Biller P, Michaux L, Pauw LD, Camboni A, Mourad M, Kanaan N.

Acta Clin Belg. 2015 Jun;70(3):218-22. doi: 10.1179/2295333714Y.0000000112. Epub 2014 Dec 26.

PMID:
25541210
13.

Clinical & immunological profile of newly diagnosed patients with youth onset diabetes mellitus.

Dhanwal DK, Agarwal S, Garg S, Agarwal P.

Indian J Med Res. 2014 Sep;140(3):356-60.

14.

Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.

Aronson R, Gottlieb PA, Christiansen JS, Donner TW, Bosi E, Bode BW, Pozzilli P; DEFEND Investigator Group.

Diabetes Care. 2014 Oct;37(10):2746-54. doi: 10.2337/dc13-0327. Epub 2014 Jul 10.

15.

Reactivation of latent viruses in individuals receiving rituximab for new onset type 1 diabetes.

Kroll JL, Beam C, Li S, Viscidi R, Dighero B, Cho A, Boulware D, Pescovitz M, Weinberg A; Type 1 Diabetes TrialNet Anti CD-20 Study Group.

J Clin Virol. 2013 Jun;57(2):115-9. doi: 10.1016/j.jcv.2013.01.016. Epub 2013 Feb 17.

16.

EBV infection and anti-CD3 treatment for Type 1 diabetes: bad cop, good cop?

Faustman DL.

Expert Rev Clin Immunol. 2013 Feb;9(2):95-7. doi: 10.1586/eci.12.101. No abstract available.

17.

Understanding risk and enhancing safety in immunotherapy trials.

Kumar D, Humar A.

Clin Infect Dis. 2013 Jan;56(2):255-7. doi: 10.1093/cid/cis855. Epub 2012 Oct 5. No abstract available.

PMID:
23042975
18.

Epstein-Barr and other herpesvirus infections in patients with early onset type 1 diabetes treated with daclizumab and mycophenolate mofetil.

Loechelt BJ, Boulware D, Green M, Baden LR, Gottlieb P, Krause-Steinrauf H, Weinberg A; Type 1 Diabetes TrialNet Daclizumab/Mycophenolic Acid Study Group.

Clin Infect Dis. 2013 Jan;56(2):248-54. doi: 10.1093/cid/cis848. Epub 2012 Oct 5.

19.

Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes.

Faustman DL, Wang L, Okubo Y, Burger D, Ban L, Man G, Zheng H, Schoenfeld D, Pompei R, Avruch J, Nathan DM.

PLoS One. 2012;7(8):e41756. doi: 10.1371/journal.pone.0041756. Epub 2012 Aug 8.

20.

Type 1 diabetes associated and tissue transglutaminase autoantibodies in patients without type 1 diabetes and coeliac disease with confirmed viral infections.

Sarmiento L, Galvan JA, Cabrera-Rode E, Aira L, Correa C, Sariego S, Fonseca M, Cubas-Dueñas I, Hung LH, Resik S, Cilio CM.

J Med Virol. 2012 Jul;84(7):1049-53. doi: 10.1002/jmv.23305.

PMID:
22585721

Supplemental Content

Loading ...
Support Center